Consumer medicine information

Stribild Tablets

Tenofovir disoproxil fumarate + Emtricitabine + Cobicistat + Elvitegravir

BRAND INFORMATION

Brand name

Stribild

Active ingredient

Tenofovir disoproxil fumarate + Emtricitabine + Cobicistat + Elvitegravir

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Stribild Tablets.

What is in this leaflet

Read all of this leaflet carefully before you start taking this medicine.

This leaflet answers some of the common questions about STRIBILD tablets. It does not contain all of the available information.

It does not take the place of talking to your doctor or pharmacist about your medical condition or treatment. If you have further questions, please ask your doctor or your pharmacist.

Keep this leaflet with your STRIBILD medicine.

You may need to read it again.

This medicine has been prescribed for you personally and you should not pass it on to others. It may harm them, even if their symptoms are the same as yours.

What is STRIBILD

STRIBILD is used to treat HIV infection. STRIBILD is for people who have never taken HIV medicines before, or who do not have a resistant HIV virus to STRIBILD.

STRIBILD consists of four medicines:

  • tenofovir disoproxil fumarate, also called tenofovir DF (VIREAD®)
  • emtricitabine or FTC (EMTRIVA®)
  • elvitegravir
  • cobicistat (TYBOST®)

These are combined in one tablet to help control Human Immunodeficiency Virus (HIV) infection.

VIREAD and EMTRIVA belong to a group of antiviral medicines known as nucleoside and nucleotide reverse transcriptase inhibitors (NRTI).

Elvitegravir belongs to a class of antiviral medicines known as integrase inhibitors.

Cobicistat is a “booster”, to help increase the levels of elvitegravir.

How STRIBILD works

HIV infection destroys CD4 T cells, which are important to the immune system. The immune system helps fight infection. After a large number of T cells are destroyed, acquired immune deficiency syndrome (AIDS) may develop.

STRIBILD helps block HIV-1 reverse transcriptase, a viral chemical in your body (enzyme) that is needed for HIV-1 to multiply. STRIBILD lowers the amount of HIV in the blood (viral load). STRIBILD may also help to increase the number of T cells (CD4+ cells), allowing your immune system to improve. Lowering the amount of HIV in the blood lowers the chance of death or infections that happen when your immune system is weak (opportunistic infections).

Use in Children and Elderly

STRIBILD is for adults. STRIBILD has not been studied in children under the age of 18 or adults over the age of 65.

Does STRIBILD cure HIV OR AIDS

STRIBILD does not cure HIV infection or AIDS.

The long-term effects of STRIBILD are not known at this time. People taking STRIBILD may still get opportunistic infections or other conditions that happen with HIV infection. Opportunistic infections are infections that develop because the immune system is weakened.

Some of these conditions are:

  • pneumonia,
  • herpes virus infections, and
  • Mycobacterium avium complex (MAC) infection.

This medicine is only available from a pharmacist after it has been prescribed by a doctor who specialises in the treatment of HIV infection.

If you wish to continue receiving treatment with STRIBILD it is important you remain under the care of a hospital or doctor who specialises in the treatment of HIV infection.

Does STRIBILD reduce the risk of passing HIV to others

STRIBILD does not lower your chance of passing HIV to other people through sexual contact, sharing needles, or being exposed to your blood.

For your health and the health of others, it is important to always practice safer sex by using a latex or polyurethane condom or other barrier to lower the chance of sexual contact with semen, vaginal secretions, or blood.

Never re-use or share needles.

Before you take STRIBILD

Who must not take it

Together with your doctor, you need to decide whether STRIBILD is right for you.

Do not take STRIBILD if you are allergic to:

  • tenofovir
  • tenofovir DF
  • emtricitabine
  • elvitegravir
  • cobicistat or
  • any of the other ingredients of STRIBILD

Some of the symptoms of an allergic reaction may include:

  • shortness of breath
  • wheezing or difficulty breathing
  • rash, itching or hives on the skin
  • swelling of the face, lips, tongue or other parts of the body

The ingredients of STRIBILD are listed in the product description section of this leaflet.

Do not take STRIBILD if you are already taking any other medicines that contain the same active ingredients.

Do not take STRIBILD if you are taking tenofovir alafenamide.

Do not take STRIBILD if you are taking other medicines that contain:

  • lamivudine (e.g. Combivir, Zeffix, Kivexa, Trizivir)
  • ritonavir (e.g. Kaletra)
  • efavirenz (e.g. Stocrin)

Do not take STRIBILD if you are already taking any of the following medicines:

  • carbamazepine (e.g. Tegretol)
  • phenobarbital
  • phenytoin (e.g. Dilantin)
  • lovastatin (e.g. Mevacor)
  • midazolam (e.g. Hypnovel)
  • rifabutin (e.g. Mycobutin)
  • rifampicin (e.g. Rifadin/Rimycin)
  • sildenafil (e.g. Viagra/Revatio)
  • simvastatin (e.g. Invast/Zimcol)
  • tadalafil (e.g. Cialis/Adcirca)
  • triazolam (e.g. Halcion)
  • St John’s Wort or products containing St John’s Wort.
  • alfuzosin hydrochloride (e.g. Xatral)
  • ergot-containing medicines like dihydroergotamine, ergotamine (e.g. Cafergot, Dihydergot, Migerot).

Do not take STRIBILD to treat your HIV infection if you are also taking adefovir dipivoxil to treat your hepatitis B virus (HBV) infection.

This is not a complete list of medicines that you should tell your doctor about.

Do not take STRIBILD after the expiry or “use by” date (EXP) printed on the bottle. If you take it after the expiry date has passed, it may not work as well.

Do not take STRIBILD if the packaging is torn or shows signs of tampering.

Before you start to take it

Tell your doctor if you take an antacid medicine that contains aluminum, magnesium hydroxide, or calcium carbonate. Take antacids at least 2 hours before or after you take STRIBILD.

Tell your doctor if you are allergic to foods, dyes, preservatives or any other medicines.

Tell your doctor if you are pregnant, or likely to become pregnant during your course of medication. We do not know if STRIBILD can harm your unborn child. You and your doctor will need to decide if STRIBILD is right for you.

Tell your doctor if you are breastfeeding, or likely to breastfeed during your course of medication. You should not breastfeed if you are HIV-positive because of the chance of passing the HIV virus to your baby. Two active substances in this medicine (tenofovir disoproxil fumarate and emtricitabine) have been found in breast milk at low concentrations.

Talk with your doctor about the best way to feed your baby.

Tell your doctor if you have kidney problems or are undergoing kidney dialysis treatment.

Tell your doctor if you have bone problems.

Tell your doctor if you have liver problems, including hepatitis B or C virus infection.

Tell your doctor if you are taking medication to treat your hepatitis C virus (HCV) infection (e.g. ledipasvir/sofosbuvir [HARVONI], sofosbuvir/velpatasvir [EPCLUSA], or sofosbuvir/velpatasvir/ voxilaprevir [VOSEVI]).

Taking other medicines

Tell your doctor or pharmacist if you are taking any other medicines including any that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines may affect the levels of STRIBILD or STRIBILD may affect the levels of other medicines in the body when they are taken at the same time as STRIBILD.

Your doctor may change your other medicines or change their doses. Other medicines, including herbal products may affect STRIBILD.

For this reason, it is very important to let your doctor or pharmacist know what medications, herbal supplements, or vitamins you are taking.

Know the medicines you take. Keep a list of medicines and show it to your doctor and pharmacist when you get a new medicine. Your doctor and your pharmacist can tell you if you can take these medicines with STRIBILD.

Do not start any new medicines while you are taking STRIBILD without first talking with your doctor or pharmacist.

How to take STRIBILD

Take the exact amount of STRIBILD your doctor has prescribed for you.

Never change the dose on your own.

Do not stop this medicine unless your healthcare provider tells you to stop.

How much to take

The usual dose is one STRIBILD tablet orally, once daily.

How to take it

Always take STRIBILD with a meal. A meal is important to get the right drug levels in your body.

A protein drink does not constitute a meal.

If you forget to take STRIBILD

Do not miss a dose of STRIBILD.

If you forget to take STRIBILD, take your missed dose right away unless it is almost time for your next dose.

Do not take a double dose to make up for a forgotten dose. Continue with your regular dosing schedule.

When your STRIBILD supply starts to run low, get more from your doctor or pharmacy. This is very important because the amount of virus in your blood may increase if the medicine is stopped for even a short time. The virus may develop resistance to STRIBILD and become harder to treat.

Do not change your dose or stop taking STRIBILD without first talking to your doctor.

If you take too much (overdose)

Immediately telephone your doctor or Poisons Information Centre: 131126 (Australia) and 0800 764 766 (New Zealand) or go to the Accident and Emergency department at your nearest hospital if you think you or anyone else may have taken too many STRIBILD tablets. Do this even if there are no signs of discomfort or poisoning. This may need urgent medical attention.

While you are taking STRIBILD

Things you must not do

Do not breastfeed. See “Before you start to take it”.

Avoid doing things that can spread HIV infection since STRIBILD does not stop you from passing the HIV infection to others:

  • Do not share needles or other injection equipment.
  • Do not share personal items that can have blood or body fluids on them, like toothbrushes or razor blades.
  • Do not have any kind of sex without protection.
    Always practice safer sex by using a latex or polyurethane condom or other barrier to reduce the chance of sexual contact with semen, vaginal secretions, or blood.

Things to be careful of

Be careful driving or operating machinery until you know how STRIBILD affects you. If you are dizzy, have trouble concentrating, or are drowsy, avoid activities that may be dangerous, such as driving or operating machinery.

SIDE EFFECTS

Like all medicines, STRIBILD can have side effects, although not everybody gets them. Some may be serious and need medical attention.

Check with your doctor as soon as possible if you have any problems while taking STRIBILD, even if you do not think the problems are connected with the medicine or are not listed in this leaflet.

STRIBILD may cause the following serious side effects:

Lactic Acidosis

If you have any of the following symptoms after taking your medication, tell your doctor IMMEDIATELY or go to the accident and emergency department at your nearest hospital:

  • You feel very weak or tired
  • You have unusual (not normal) muscle pain
  • You have trouble breathing
  • You have stomach pain with nausea and vomiting
  • You feel cold, especially in your arms and legs
  • You feel dizzy or light headed
  • You have a fast or irregular heartbeat

These side effects may be due to a condition called lactic acidosis (build-up of an acid in the blood).

Lactic acidosis can be a medical emergency and may need to be treated in the hospital.

Serious Liver Problems (hepatotoxicity)

If you have any of the following symptoms while taking your medication, tell your doctor IMMEDIATELY or go to the accident and emergency department at your nearest hospital:

  • Your skin or the white part of your eyes turns yellow (jaundice)
  • Your urine turns dark
  • Your bowel movements (stools) turn light in colour
  • You don’t feel like eating food for several days or longer
  • You feel sick to your stomach (nausea)
  • You have lower stomach area (abdominal) pain

These side effects may be due to a condition called hepatotoxicity with liver enlargement (hepatomegaly) and fat deposits in the liver (steatosis) which sometimes occurs in patients taking anti-HIV medicines.

You may be more likely to get lactic acidosis or liver problems if you are female, very overweight (obese), or have been taking similar nucleoside analog-containing medicines, like STRIBILD, for a long time.

Hepatic Flares

If you have HIV infection and HBV infection you should not stop your STRIBILD treatment without first discussing this with your doctor. Some patients have had blood tests or symptoms indicating a worsening of their hepatitis (“hepatic flare”) after stopping individual components (tenofovir DF and emtricitabine) of STRIBILD.

You may require medical exams and blood tests for several months after stopping treatment. STRIBILD is not approved for the treatment of HBV, so you must discuss your HBV therapy with your doctor.

Kidney Problems

If you have had kidney problems in the past or take other medicines that can cause kidney problems, your doctor should do regular blood tests to check your kidneys.

Symptoms that may be related to kidney problems include a high volume of urine, thirst, muscle pain, and muscle weakness.

Changes in Bone Mineral Density (thinning bones)

Laboratory tests show changes in the bones of patients treated with tenofovir DF, a component of STRIBILD.

Some people living with HIV treated with VIREAD developed thinning of the bones (osteopaenia).

If you have had bone problems in the past, your doctor may need to do tests to check your bone mineral density or may prescribe medicines to help your bone mineral density.

Additionally, bone pain and softening of the bone (which may contribute to fractures) may occur as a consequence of kidney problems.

Signs and Symptoms of Inflammation

In some patients with advanced HIV infection (AIDS), signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. It is believed that these symptoms are due to an improvement in the body’s immune response, which lets the body fight infections that may have been present with no obvious symptoms.

If you notice any symptoms of infection, please tell your doctor immediately.

Pancreatitis

If you have any of the following symptoms after starting your medication, tell your doctor IMMEDIATELY or go to the accident and emergency department at your nearest hospital:

  • severe stomach pain or cramps
  • nausea
  • vomiting

These side effects may be due to a condition called pancreatitis which sometimes occurs in patients taking anti-HIV medicines.

Common Side Effects:

The most common side effects of STRIBILD are:

  • diarrhoea
  • upper respiratory tract infection
  • depression

Other side effects include:

  • vomiting
  • nausea
  • headache
  • intestinal gas
  • dizziness
  • back pain
  • tiredness
  • sleeping problems (including difficulty falling asleep or sleepiness)
  • bronchitis
  • abnormal dreams
  • stomach pain or discomfort
  • rash
  • serious kidney problems

Tell your doctor if you notice anything else that is making you feel unwell.

Talk to your doctor or pharmacist if you don’t understand anything in this list.

Ask your doctor or pharmacist for a more complete list of side effects of STRIBILD and all the medicines you will take. This is not a complete list of side effects possible with STRIBILD.

After taking STRIBILD

Storage

Keep STRIBILD tablets where children cannot reach them. A locked cupboard at least one-and-a half metres above the ground is a good place to store them.

Keep STRIBILD tablets in a cool, dry place where it stays below 30 °C.

Do not store STRIBILD or any other medicine in a bathroom or near a sink.

Do not leave STRIBILD in the car or on a window sill. Heat and dampness can destroy some medicines.

Keep your STRIBILD tablets in the bottle with the cap tightly closed until you take them. If you take STRIBILD tablets out of their pack they may not keep well.

PRODUCT DESCRIPTION

What the tablets look like

STRIBILD is the brand name of your medicine.

STRIBILD tablets are capsule-shaped and green in colour.

Each tablet is debossed with “GSI” on one side and the number “1” surrounded by a square box ( ) on the other side.

STRIBILD tablets are supplied in bottles containing 30 tablets.

Ingredients

Each STRIBILD tablet contains the following active ingredients:

  • elvitegravir
  • cobicistat
  • tenofovir disoproxil fumarate
  • emtricitabine

Each STRIBILD tablet also contains the following ingredients:

  • lactose
  • cellulose-microcrystalline (E460)
  • silicon dioxide
  • croscarmellose sodium
  • hyprolose
  • magnesium stearate (E572)
  • sodium lauryl sulphate

Film-coating:

  • indigo carmine (FD&C blue #2)
  • aluminum lake
  • macrogol 3350
  • polyvinyl alcohol
  • talc
  • titanium dioxide (E171)
  • yellow iron oxide

SPONSOR

STRIBILD tablets are supplied in Australia by:

Gilead Sciences Pty Ltd
Level 6, 417 St Kilda Road
Melbourne, Victoria 3004

In New Zealand by:

Gilead Sciences (NZ)
c/- Grant Thornton New Zealand Limited
Level 4, 152 Fanshawe Street,
Auckland 1010

Date of preparation: 15 July 2020

AUST R 194081

ATRIPLA, EPCLUSA, HARVONI, STRIBILD, GENVOYA, DESCOVY, ODEFSEY, EMTRIVA, TRUVADA, EVIPLERA, VIREAD, VOSEVI and GSI are trademarks of Gilead Sciences, Inc. or one of its related companies. All other trademarks referenced herein are the property of their respective owners.

Published by MIMS September 2020

BRAND INFORMATION

Brand name

Stribild

Active ingredient

Tenofovir disoproxil fumarate + Emtricitabine + Cobicistat + Elvitegravir

Schedule

S4

 

1 Name of Medicine

Stribild (tenofovir disoproxil fumarate/emtricitabine/elvitegravir/cobicistat).

2 Qualitative and Quantitative Composition

The active substances in Stribild tablets are tenofovir disoproxil fumarate (tenofovir DF), emtricitabine, elvitegravir and cobicistat. Each tablet contains 300 mg tenofovir DF (which is equivalent to 245 mg of tenofovir disoproxil), 200 mg emtricitabine, 150 mg of elvitegravir and 150 mg of cobicistat.
Tenofovir DF is a white to off-white crystalline powder with a solubility of 13.4 mg/mL in water at 25°C. The partition coefficient (log p) for tenofovir disoproxil is 1.25 and the pKa is 3.75.
Emtricitabine is a white to off-white crystalline powder with a solubility of approximately 112 mg/mL in water at 25°C. The partition coefficient (log p) for emtricitabine is -0.43 and the pKa is 2.65.
Elvitegravir is a white to pale yellow powder with a solubility of less than 0.5 microgram/mL in water at 20°C. The partition coefficient (log p) for elvitegravir is 4.5 and the pKa is 6.6.
Cobicistat is a white to pale yellow solid with a solubility of 0.1 mg/mL in water with pH 6.8 phosphate buffer at 20°C. The partition coefficient (log p) for cobicistat is 4.3 and the pKa is 6.4.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Stribild is available as tablets. The tablets are film-coated, capsule shaped and green in colour. Each tablet is debossed with 'GSI' on one side and the number "1" surrounded by a square box on the other side.

4 Clinical Particulars

4.9 Overdose

If overdose occurs the patient must be monitored for evidence of toxicity. Treatment of overdose with Stribild consists of general supportive measures including monitoring of vital signs and ECG (QT interval) as well as observation of the clinical status of the patient.
For information on the management of overdose, contact the Poison Information Centre on 131126 (Australia) and 0800 764 766 (New Zealand).
Tenofovir disoproxil fumarate. Clinical experience of doses higher than the therapeutic dose of Viread 300 mg is available from two studies. In one study, intravenous tenofovir, equivalent to 16.7 mg/kg/day of tenofovir DF, was administered daily for 7 days. In the second study, 600 mg of tenofovir DF was administered to patients orally for 28 days. No unexpected or severe adverse reactions were reported in either study. The effects of higher doses are not known.
Tenofovir is efficiently removed by haemodialysis with an extraction coefficient of approximately 54%. Following a single 300 mg dose of Viread, a four hour haemodialysis session removed approximately 10% of the administered tenofovir dose.
Emtricitabine. Limited clinical experience is available at doses higher than the therapeutic dose of Emtriva. In one clinical pharmacology study single doses of emtricitabine 1200 mg were administered to 11 patients. No severe adverse reactions were reported. The effects of higher doses are not known.
Haemodialysis treatment removes approximately 30% of the emtricitabine dose over a 3 hour dialysis period starting within 1.5 hours of emtricitabine dosing (blood flow rate of 400 mL/min and a dialysate flow rate of 600 mL/min). It is not known whether emtricitabine can be removed by peritoneal dialysis.
Elvitegravir. Limited clinical experience is available at doses higher than the therapeutic dose of elvitegravir. In one study, boosted elvitegravir equivalent to 2 times the therapeutic dose of 150 mg once daily for 10 days was administered to 42 healthy subjects. No severe adverse reactions were reported. The effects of higher doses are not known. As elvitegravir is highly bound to plasma proteins, it is unlikely that it will be significantly removed by haemodialysis or peritoneal dialysis.
Cobicistat. Limited clinical experience is available at doses higher than the therapeutic dose of cobicistat. In two studies, single dose of cobicistat 400 mg was administered to a total of 60 healthy subjects. No severe adverse reactions were reported. The effects of higher doses are not known. As cobicistat is highly bound to plasma proteins, it is unlikely that it will be significantly removed by hemodialysis or peritoneal dialysis.

5 Pharmacological Properties

5.3 Preclinical Safety Data

Tenofovir disoproxil fumarate. Tenofovir and tenofovir DF administered in toxicology studies to rats, dogs and monkeys at exposures (based on AUCs) greater than or equal to 6-fold those observed in humans caused bone toxicity. In monkeys the bone toxicity was diagnosed as osteomalacia. Osteomalacia observed in monkeys appeared to be reversible upon dose reduction or discontinuation of tenofovir. In rats and dogs, the bone toxicity manifested as reduced bone mineral density. The mechanism(s) underlying bone toxicity is unknown.
Evidence of renal toxicity was noted in 4 animal species. Increases in serum creatinine, BUN, glycosuria, proteinuria, phosphaturia and/or calciuria and decreases in serum phosphate were observed to varying degrees in these animals. These toxicities were noted at exposures (based on AUCs) 2 to 20 times higher than those observed in humans. The relationship of the renal abnormalities, particularly the phosphaturia, to the bone toxicity is not known.
Genotoxicity. No genotoxicity studies have been conducted with tenofovir DF, emtricitabine, elvitegravir and cobicistat in combination.
Tenofovir disoproxil fumarate was mutagenic in an in vitro mouse L5178Y lymphoma cell assay (tk locus) and in an ex vivo assay for unscheduled DNA synthesis in rat hepatocytes, but it was negative in in vitro bacterial assays for gene mutation and an in vivo mouse micronucleus test for chromosomal damage.
Emtricitabine was not mutagenic in bacteria or mouse lymphoma cell assays in vitro nor clastogenic in the mouse micronucleus test in vivo.
Elvitegravir showed an equivocal response in an in vitro chromosomal aberration assay in Chinese hamster lung cells, but only in the absence of metabolic activation. No genotoxicity was observed in a test for bacterial reverse mutation in vitro, or in vivo rat micronucleus test.
Cobicistat was not genotoxic in in vitro tests for bacterial reverse gene mutation or gene mutation in mouse lymphoma L5178Y cells (tk locus), or in an in vivo rat micronucleus test.
Carcinogenicity. No carcinogenicity studies have been conducted with tenofovir DF, emtricitabine, elvitegravir and cobicistat in combination.
Tenofovir disoproxil fumarate. In a long-term carcinogenicity study conducted in mice with tenofovir DF there was a low incidence of duodenal tumours with the highest dose of 600 mg/kg/day. These were associated with a high incidence of duodenal mucosal hyperplasia, which was also observed with a dose of 300 mg/kg/day. These findings may be related to high local drug concentrations in the gastrointestinal tract, likely to result in much higher exposure margins than that based on the AUC. At therapeutic doses the risk of these duodenal effects occurring in humans is likely to be low. The systemic drug exposure (AUC) with the 600 mg/kg/day dose was approximately 15 times the human exposure at the therapeutic dose of 300 mg/day. No tumourigenic response was observed in rats treated with doses of up to 300 mg/kg/day (5 times the human systemic exposure at the therapeutic dose based on AUC).
Emtricitabine. In long-term oral carcinogenicity studies conducted with emtricitabine, no drug related increases in tumour incidence were found in mice at doses up to 750 mg/kg/day (32 times the human systemic exposure (AUC) at the therapeutic dose of 200 mg/day) or in rats at doses up to 600 mg/kg/day (38 times the human systemic exposure at the therapeutic dose).
Elvitegravir. In a long-term carcinogenicity study in mice, no tumourigenic response was seen with doses of up to 2000 mg/kg/day, with the highest dose also being given together with 25 mg/kg/day ritonavir. Respective elvitegravir exposures (AUC) with this dose were approximately 3.1 and 14 times the human exposure with the 150 mg/day dose. No tumourigenic response was seen in a long-term study in rats with doses up to 2000 mg/kg/day (12 times in males and 27 times in females the human exposure (AUC) with the therapeutic dose).
Cobicistat. In a long-term study in mice with doses of up to 50 mg/kg/day in males and 100 mg/kg/day in females (9-21 times the human exposure (AUC) at 150 mg daily), cobicistat treatment did not result in any increased tumour incidences. In a corresponding study, with doses of up to 50 mg/kg/day in males and 30 mg/kg/day in females (1.9-2.6 times the human exposure with 150 mg daily), treatment resulted in increased incidence of thyroid follicular cell tumours. Hepatocyte hypertrophy was also observed, and this oncogenic response is most likely related to alterations in thyroid hormones and to be specific to species.

6 Pharmaceutical Particulars

6.7 Physicochemical Properties

Chemical structure. Tenofovir disoproxil fumarate. Tenofovir DF is a fumaric acid salt of the bis-isopropoxycarbonyloxymethyl ester derivative of tenofovir. The chemical name of tenofovir DF is 9-[(R)2 [[bis[[(isopropoxycarbonyl)oxy] methoxy]phosphinyl]methoxy]propyl]adenine fumarate (1:1). It has a molecular formula of C19H30N5O10P.C4H4O4 and a molecular weight of 635.52. It has the following structural formula:
https://stagingapi.mims.com/au/public/v2/images/fullchemgif/CSTENDIS.gif Emtricitabine. The chemical name of emtricitabine is 5-fluoro-1-(2R,5S)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Emtricitabine is the (-) enantiomer of a thio analog of cytidine, which differs from other cytidine analogs in that it has a fluorine in the 5-position.
It has a molecular formula of C8H10FN3O3S and a molecular weight of 247.24. It has the following structural formula:
https://stagingapi.mims.com/au/public/v2/images/fullchemgif/CSEMTRIC.gif Elvitegravir. The chemical name of elvitegravir is 3-quinolinecarboxylic acid, 6-[(3-chloro-2-fluorophenyl)-methyl]- 1,4-dihydro-1-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-7-methoxy-4-oxo-. It has a molecular formula of C23H23ClFNO5 and a molecular weight of 447.9. It has the following structural formula:
https://stagingapi.mims.com/au/public/v2/images/fullchemgif/CSELVITE.gif Cobicistat. The chemical name for cobicistat is 1,3-Thiazol-5-ylmethyl [(2R,5R)-5-{[(2S)-2-[(methyl{[2-(propan-2-yl)- 1,3-thiazol-4-yl]methyl}carbamoyl)amino]-4-(morpholin-4-yl) butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate. It has a molecular formula of C40H53N7O5S2 and a molecular weight of 776.0. It has the following structural formula:
https://stagingapi.mims.com/au/public/v2/images/fullchemgif/CSCOBICI.gif CAS number. Tenofovir DF CAS registry number: 202138-50-9.
Emtricitabine CAS registry number: 143491-57-0.
Elvitegravir CAS registry number: 697761-98-1.
Cobicistat CAS registry number: 1004316-88-4.

7 Medicine Schedule (Poisons Standard)

S4.

Summary Table of Changes

https://stagingapi.mims.com/au/public/v2/images/fulltablegif/STRIBIST.gif